Control of Heterologous Simian Immunodeficiency Virus SIV smE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques

• Published in: Journal of virology 2018-08, Vol.92 (15)
• Main Authors: Singh, Shakti, Ramírez-Salazar, Eric G, Doueiri, Rami, Valentin, Antonio, Rosati, Margherita, Hu, Xintao, Keele, Brandon F, Shen, Xiaoying, Tomaras, Georgia D, Ferrari, Guido, LaBranche, Celia, Montefiori, David C, Das, Jishnu, Alter, Galit, Trinh, Hung V, Hamlin, Christopher, Rao, Mangala, Dayton, Frances, Bear, Jenifer, Chowdhury, Bhabadeb, Alicea, Candido, Lifson, Jeffrey D, Broderick, Kate E, Sardesai, Niranjan Y, Sivananthan, Sandra J, Fox, Christopher B, Reed, Steven G, Venzon, David J, Hirsch, Vanessa M, Pavlakis, George N, Felber, Barbara K
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - pharmacology; Amino Acid Substitution; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Gene Products, env - genetics; Gene Products, env - immunology; Gene Products, env - pharmacology; Immunity, Humoral; Immunization; Macaca; Mutation, Missense; SAIDS Vaccines - genetics; SAIDS Vaccines - immunology; SAIDS Vaccines - pharmacology; Simian Acquired Immunodeficiency Syndrome - genetics; Simian Acquired Immunodeficiency Syndrome - immunology; Simian Acquired Immunodeficiency Syndrome - prevention & control; Simian Immunodeficiency Virus - genetics; Simian Immunodeficiency Virus - immunology; Toll-Like Receptor 4 - agonists; Toll-Like Receptor 4 - immunology; Vaccines, DNA - genetics; Vaccines, DNA - immunology; Vaccines, DNA - pharmacology
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/JVI.00281-18

We developed a method of simultaneous vaccination with DNA and protein resulting in robust and durable cellular and humoral immune responses with efficient dissemination to mucosal sites and protection against simian immunodeficiency virus (SIV) infection. To further optimize the DNA-protein coimmunization regimen, we tested a SIV -based vaccine formulated with either of two Toll-like receptor 4 (TLR4) ligand-based liposomal adjuvant formulations (TLR4 plus TLR7 [TLR4+7] or TLR4 plus QS21 [TLR4+QS21]) in macaques. Although both vaccines induced humoral responses of similar magnitudes, they differed in their functional quality, including broader neutralizing activity and effector functions in the TLR4+7 group. Upon repeated heterologous SIV challenge, a trend of delayed viral acquisition was found in vaccinees compared to controls, which reached statistical significance in animals with the TRIM-5α-resistant (TRIM-5α R) allele. Vaccinees were preferentially infected by an SIV transmitted/founder virus carrying neutralization-resistant A/K mutations at residues 45 and 47 in Env, demonstrating a strong vaccine-induced sieve effect. In addition, the delay in virus acquisition directly correlated with SIV -specific neutralizing antibodies. The presence of mucosal V1V2 IgG binding antibodies correlated with a significantly decreased risk of virus acquisition in both TRIM-5α R and TRIM-5α-moderate/sensitive (TRIM-5α M/S) animals, although this vaccine effect was more prominent in animals with the TRIM-5α R allele. These data support the combined contribution of immune responses and genetic background to vaccine efficacy. Humoral responses targeting V2 and SIV-specific T cell responses correlated with viremia control. In conclusion, the combination of DNA and gp120 Env protein vaccine regimens using two different adjuvants induced durable and potent cellular and humoral responses contributing to a lower risk of infection by heterologous SIV challenge. An effective AIDS vaccine continues to be of paramount importance for the control of the pandemic, and it has been proven to be an elusive target. Vaccine efficacy trials and macaque challenge studies indicate that protection may be the result of combinations of many parameters. We show that a combination of DNA and protein vaccinations applied at the same time provides rapid and robust cellular and humoral immune responses and evidence for a reduced risk of infection. Vaccine-induced neutralizing antibodies and Env V